Proceedings (Apr 2019)

Targeting the Resistance in Multiple Myeloma

  • Micaela Freitas,
  • Mark E. Issa,
  • Muriel Cuendet

DOI
https://doi.org/10.3390/proceedings2019011003
Journal volume & issue
Vol. 11, no. 1
p. 3

Abstract

Read online

Multiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic strategies to overcome this resistance, which is partly attributed to a subpopulation of cells known as cancer stem cells. Withanolides and HDAC6 selective inhibitors were identified as promising compounds in various resistant multiple myeloma models.

Keywords